Protective effects of dihydropyridine Ca-blockers against endothelial cell oxidative injury due to combined nitric oxide and superoxide

Pharmacological Research

Volumn 45, Issue 1, 2002, Pages 27-33

  Mak, I Tong ^a   Zhang, Jingyun ^a   Weglicki, William B ^a  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

DHP Ca blockers; Endothelial cell injury; Nitric oxide; Peroxynitrite; SIN 1

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE; NICARDIPINE; NIFEDIPINE; NISOLDIPINE; NITRIC OXIDE; PEROXYNITRITE; SUPEROXIDE; TROLOX C;

ANTIOXIDANT ACTIVITY; ARTICLE; CELL FREE SYSTEM; CELL LINE; CELL PROTECTION; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; CYTOTOXICITY; DRUG EFFECT; ENDOTHELIUM CELL; IC 50; INCUBATION TIME; LIPID PEROXIDATION; LIPOPHILICITY; OXIDATION; PRIORITY JOURNAL; TIME;

EID: 0036447374     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.2001.0903     Document Type: Article

References (36)

1. Miller MJ, Sandoval M. Nitric oxide. III. A molecular prelude to intestinal inflammation. Am J Physiol 1999; 276: G795-9.
2. Stoclet JC, Muller B, Gyorgy K, Andriantsiothaina R, Kleschyov AL. The inducible nitric oxide synthase in vascular and cardiac tissue. Eur J Pharmacol 1999; 375: 139-55.
3. Crow JP, Beckman JS. Reactions between nitric oxide, superoxide, and peroxynitrite. Footprints of peroxynitrite in vivo. Adv Pharmacol 1995; 34: 17-43.
4. Ischiropoulos H, Zhu L, Beckman JS. Peroxynitrite formation from macrophage-derived nitric oxide. Arch Biochem Biophys 1992; 298: 446-51.
5. Radi R, Beckman JS, Bush KM, Freeman BA. Peroxynitrite oxidation of sulfhydryls. The cytosolic potential of superoxide and nitric oxide. J Biol Chem 1994; 266: 4244-50.
6. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. Apparent hydroxyl radical production from peroxynitrite: Implications for endothelial cell injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 1990; 87: 1620-4.
7. Koppenol WH. The basic chemistry of nitrogen monoxide and peroxynitrite. Free Radic Biol Med 1998; 25: 385-91.
8. Mak IT, Freedman AM, Dickens BF, Weglicki WB. Protective effects of sulfhydryl-containing ACE inhibitors against free radicals injury in endothelial cells. Biochem Pharmacol 1990; 40: 2169-75.
9. Mak IT, Boehme P, Weglicki WB. Antioxidant protective effects of calcium channel blockers against free radical injury in endothelial cells: Correlation with preservation of glutathione levels. Circ Res 1992; 70: 1099-103.
10. Mak IT, Kramer JH, Weglicki WB. Antioxidant properties of active and inactive isomers of nicardipine in cardiac membranes endothelial cells and perfused rat hearts. Coron Artery Dis 1992; 3: 1095-103.
11. Mak IT, Boheme P, Weglicki WB. Protective effects of calcium channel blockers against free radical-impaired endothelial cell proliferation. Biochem Pharmacol 1995; 50: 1531-4.
12. Beckman JS, Chen J, Ischiropoulos H, Crow JP. Oxidative chemistry of peroxynitrite. Methods Enzymol 1994; 233: 229-40.
13. Mak IT, Komarov A, Wagner T, Stafford R, Dickens BF, Weglicki WB. Enhanced nitric oxide production during Mg-deficiency and its role in mediating red cell glutathione loss. Am J Physiol 1996; 271: C385-90.
14. Brunelli L, Crow JP, Beckman JS. The comparative toxicity of nitric oxide and peroxynitrite to E. Coli. Arch Biochem Biophys 1995; 316: 327-34.
15. Mak IT, Weglicki WB. Membrane antiperoxidative activities of D-and L-enantiomers and dimethyl quaternary analog of propranolol. Pharmacol Res 1992; 25: 25-30.
16. Mak IT, Weglicki WB. Comparative antioxidant activities of propranolol, nifedipine, verapamil and diltiazem against sarcolemmal membrane lipid peroxidation. Circ Res 1990; 66: 1449-52.
17. Mak IT, Weglicki. Antioxidant properties of calcium channel blocking drugs. Method Enzymol 1994; 234 (Part D): 620-30.
18. Janero DR, Burgardt B. Antiperoxidant effects of dihydropyridines calcium antagonists. Biochem Pharmacol 1989; 38: 4344-8.
19. Aruoma OI, Smith C, Cecchini R, Evans PJ, Halliwell B. Free radical scavenging and inhibition of lipid peroxidation by β-blockers and by agents that interfere with calcium metabolism. Biochem Pharmacol 1991; 42: 735-43.
20. Henry PD. Antiperoxidative actions of calcium antagonists and atherogenesis. J Cardiovasc Pharmacol 1991; 18: S6-10.
21. Hogg N, Kalyanaraman B. Nitric oxide and lipid peroxidation. Biochem Biophys Acta 1999; 1411: 378-84.
22. Jongkind JF, Verkerk A, Baggen RGA. Glutathione metabolism of human vascular endothelial cells under peroxidative stress. Free Radic Biol Med 1989; 7: 507-12.
23. Weglicki WB, Mak IT, Simic MG. Mechanisms of cardiovascular drugs as antioxidants. J Mol Cell Cardiol 1990; 22: 1199-1208.
24. Simic MG, Hunter E, Jovanovic SV. Electron versus H-atom transfer in chemical repair. In: Anticarcinogenesis and Radiation Protection. Cerutti P, Nygaard OF, Simic MG, eds. New York: Plenum, 1987: 17-24.
25. Fodor JG. Nisoldipine CC: efficacy and tolerability in hypertension and ischemic heart disease. Cardiovasc Drugs Ther 1997; Suppl 3: 873-9.
26. Mason RP, Rhodes DG, Herbette LG. Reevaluation equilibrium and kinetic binding parameters for lipophilic drugs based on a structural model for drug interaction with biological membranes. J Med Chem 1991; 34: 869-77.
27. Diaz-Araya G, Godoy L, Naranjo L, Squella JA, Letelier ME, Nunez-Vergara LJ. Antioxidant effects of 1,4-dihydropyridine and nitroso aryl derivatives on Fe/ascorbate-stimulated lipid peroxidation in rat brain slices. Gen Pharmacol 1998; 31: 385-91.
28. Willis AL, Nagel B, Churchhill V, Whyte MA, Smith DL, Mahmud I, Puppione DL. Antiatherosclerotic effects of nicardipine and nifedipine in cholesterol-fed rabbits. Atherosclerosis 1985; 68: 1366-9.
29. Henry PD. Atherosclerosis, calcium and calcium antagonists. Circulation 1985; 72: 456-9.
30. Keogh AM, Schroeder JS. Calcium antagonists and atherosclerosis. Reperfusion 1990; 2: 5-8.
31. Herbette LG, Vant Erve YMH, Rhodes DG. Interaction of 1,4-dihydropyridine calcium antagonists with biological membranes: Lipid bilayer partitioning could occur before drug binding to receptors. J Mol Cell Cardiol 1989; 21: 187-201.
32. Mason RP, Trumbore MW. Differential membrane interactions of calcium channel blockers: Implication for antioxidant activity. Biochem Pharmacol 1996; 51: 653-60.
33. Kaur H, Halliwell B. Evidence for nitric oxide-mediated oxidative damage in chronic inflammation. Nitrotyrosine in serum and synovial fluid from rheumatoid patients. FEBS Lett 1994; 350: 9-12.
34. Buttery LD, Springall DR, Chester AH, Evans TJ, Standfield EN, Parums DV, Yacoub MH, Polak JM. Inducible nitric oxide synthase is present within human atherosclerotic lesions and promotes the formation and activity of peroxynitrite. Lab Invest 1996; 75: 77-85.
35. Dusting GJ, Fennessy P, Yin ZL, Gurevich V. Nitric oxide in atherosclerosis: vascular protector or villain. Clin Exp Pharmacol Physiol 1998; (Suppl. 25): S34-41.
36. Patel RP, Levonen A, Crawford JH, Darley-Usmar VM. Mechanisms of the pro- and anti-oxidant actions of nitric oxide in atheroslerosis. Cardiovasc Res 2000; 47: 465-74.